Literature DB >> 30275744

Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Toshihide Ogawa1, Shinya Fujii1, Keita Kuya1, Shin-Ichiro Kitao1, Yuki Shinohara1, Mana Ishibashi1, Yoshio Tanabe1.   

Abstract

An accurate diagnosis of Parkinson's disease (PD) is a prerequisite for therapeutic management. In spite of recent advances in the diagnosis of parkinsonian disorders, PD is misdiagnosed in between 6 and 25% of patients, even in specialized movement disorder centers. Although the gold standard for the diagnosis of PD is a neuropathological assessment, neuroimaging has been playing an important role in the differential diagnosis of PD and is used for clinical diagnostic criteria. In clinical practice, differential diagnoses of PD include atypical parkinsonian syndromes such as dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, caused by a striatal dopamine deficiency following nigrostrial degeneration. PD may also be mimicked by syndromes not associated with a striatal dopamine deficiency such as essential tremor, drug-induced parkinsonism, and vascular parkinsonism. Moreover, difficulties are associated with the clinical differentiation of patients with parkinsonism from those with Alzheimer's disease. In this review, we summarize the typical imaging findings of PD and its related diseases described above using morphological imaging modalities (conventional MR imaging and neuromelanin MR imaging) and functional imaging modalities (99mTc-ethyl cysteinate dimer perfusion single photon emission computed tomography, 123I-metaiodobenzylguanidine myocardial scintigraphy, and 123I-FP-CIT dopamine transporter single photon emission computed tomography) that are clinically available in most hospitals. We also attempt to provide a diagnostic approach for the differential diagnosis of PD and its related diseases in clinical practice.

Entities:  

Keywords:  123I-FP-CIT dopamine transporter imaging; 123I-metaiodobenzylguanidine myocardial scintigraphy; Parkinson’s disease; atypical parkinsonian syndrome; neuromelanin-sensitive MR imaging

Year:  2018        PMID: 30275744      PMCID: PMC6158357     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  55 in total

Review 1.  Parkinson's disease: diagnosis.

Authors:  David J Brooks
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

3.  Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy.

Authors:  F Miyoshi; T Ogawa; S-i Kitao; M Kitayama; Y Shinohara; M Takasugi; S Fujii; T Kaminou
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-06       Impact factor: 3.825

Review 4.  Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice?

Authors:  A Stefanelli; G Treglia; I Bruno; V Rufini; A Giordano
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-05       Impact factor: 3.507

5.  Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor.

Authors:  G Nicoletti; D Manners; F Novellino; F Condino; E Malucelli; B Barbiroli; C Tonon; G Arabia; M Salsone; L Giofre'; C Testa; P Lanza; R Lodi; A Quattrone
Journal:  Neurology       Date:  2010-03-23       Impact factor: 9.910

6.  Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  Jong-Min Kim; Hye-Jin Jeong; Yun Jung Bae; Sung-Yeon Park; Eunhee Kim; Seo Young Kang; Eung Seok Oh; Kyeong Joon Kim; Beomseok Jeon; Sang Eun Kim; Zang-Hee Cho; Young-Bo Kim
Journal:  Parkinsonism Relat Disord       Date:  2016-02-23       Impact factor: 4.891

7.  Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies.

Authors:  Nicole Chow; Dag Aarsland; Hedieh Honarpisheh; Mona K Beyer; Johanne H Somme; David Elashoff; Arvid Rongve; Ole B Tysnes; Paul M Thompson; Liana G Apostolova
Journal:  Dement Geriatr Cogn Disord       Date:  2012-08-20       Impact factor: 2.959

8.  Individualized parcellation of the subthalamic nucleus in patients with Parkinson's disease with 7T MRI.

Authors:  Birgit R Plantinga; Yasin Temel; Yuval Duchin; Kâmil Uludağ; Rémi Patriat; Alard Roebroeck; Mark Kuijf; Ali Jahanshahi; Bart Ter Haar Romenij; Jerrold Vitek; Noam Harel
Journal:  Neuroimage       Date:  2016-09-26       Impact factor: 6.556

Review 9.  Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.

Authors:  Giovanni Rizzo; Massimiliano Copetti; Simona Arcuti; Davide Martino; Andrea Fontana; Giancarlo Logroscino
Journal:  Neurology       Date:  2016-01-13       Impact factor: 9.910

Review 10.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.

Authors:  Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-28       Impact factor: 9.236

View more
  2 in total

Review 1.  Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers.

Authors:  Lara Cheslow; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-05-14       Impact factor: 2.498

2.  Prevalence of Parkinsonism Among Foundry Workers in an Automobile Manufacturing Factory in Tehran.

Authors:  Mohammad Rohani; Negin Kassiri; Maziar Emamikhah Abarghouei; Saber Mohammadi; Yasser Labbafinejad
Journal:  Cureus       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.